British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015 by Ling, T. C. et al.
                                                              
University of Dundee
British Association of Dermatologists and British Photodermatology Group guidelines
for the safe and effective use of psoralen-ultraviolet A therapy 2015
Ling, T. C.; Clayton, T. H.; Crawley, J.; Exton, L. S.; Goulden, V.; Ibbotson, S.; McKenna, K.;
Mohd Mustapa, M. F.; Rhodes, L. E.; Sarkany, R.; Dawe, R. S.
Published in:
British Journal of Dermatology
DOI:
10.1111/bjd.14317
Publication date:
2016
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Ling, T. C., Clayton, T. H., Crawley, J., Exton, L. S., Goulden, V., Ibbotson, S., ... Dawe, R. S. (2016). British
Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of
psoralen-ultraviolet A therapy 2015. British Journal of Dermatology, 174(1), 24-55. [14317]. DOI:
10.1111/bjd.14317
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
1 
British Association of Dermatologists and British Photodermatology Group 
guidelines for the safe and effective use of PUVA therapy 2015 
TC Ling, TH Clayton, J Crawley,* LS Exton,† V Goulden,‡ S Ibbotson,§ K McKenna,¶ MF 
Mohd Mustapa,†  LE Rhodes,π R Sarkany,* RS Dawe§ 
Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, Manchester M6 8HD; 
*Department of Dermatology, University College Hospital, 235 Euston Road, London NW1
2BU; †British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, 
W1T5HQ, ‡Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, West 
Yorkshire LS7 4SA; §Department of Dermatology, Ninewells Hospital & Medical School, 
University of Dundee, Dundee DD1 9SY; ¶Department of Dermatology, Belfast City Hospital, 
Belfast BT9 7AB; πDermatology Research Centre, Faculty of Medical and Human Sciences, 
University of Manchester, Salford Royal Foundation Trust, Manchester M6 8HD 
Corresponding author:  
Tsui Ling, Tsui.Ling@srft.nhs.uk; guidelines@bad.org.uk 
TCL, THC, JC, VG, SI, KMcK, LER, RS and RSD are members of the guideline development 
group with technical support from LSE and MFMM. 
Footnote: 
This is an updated set of guidelines prepared for the British Association of Dermatologists’ 
(BAD) Clinical Standards Unit, which includes the Therapy & Guidelines Sub-committee. 
Members of the Clinical Standards Unit that have been involved are: PM McHenry [Chairman 
T&G], JR Hughes, M Griffiths, AJ McDonagh, DA Buckley, I Nasr, VJ Swale, CE Duarte 
Williamson, NJ Levell, T Leslie, E Mallon, S Wakelin, P Hunasehally, MJ Cork, S Ungureanu, 
J Donnelly [British National Formulary], K Towers [British National Formulary], C Saunders 
[British Dermatological Nursing Group], R Davis [British Dermatological Nursing Group], AG 
Brain [BAD Scientific Administrator], LS Exton [BAD Information Scientist], MF Mohd Mustapa 
[BAD Clinical Standards Manager]. 
These guidelines were first produced by the British Photodermatology Group in 1994 
(oral PUVA) and in 2000 (topical PUVA)  
This update was produced jointly by the British Photodermatology Group and the 
British Association of Dermatologists 
Conflicts of interest: 
THC (1) advisory board payment – Johnson & Johnson (non-specific); (2) conference 
organising fee – Galderma (non-specific); SI (1) travel expenses and honoraria – Galderma, 
Spirit and Ambicare Health (non-specific); (2) research support – Ambicare Health (non-
specific) 
Key words: photochemotherapy; phototherapy; psoralens; PUVA; guidelines; treatment; 
safety. 
This is the peer reviewed version of the following article: Ling, T.C., Clayton, T.H., Crawley, J., 
Exton, L.S., Goulden, V., Ibbotson, S., McKenna, K., Mohd Mustapa, M.F., Rhodes, L.E., 
Sarkany, R. and Dawe, R.S. (2016), British Association of Dermatologists and British 
Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A 
therapy 2015. Br J Dermatol, 174: 24–55., which has been published in final form at doi:10.1111/
bjd.14317. This article may be used for non-commercial purposes in accordance with Wiley 
Terms and Conditions for Self-Archiving.
2 
 
 
 
NICE has accredited the process used by the British Association of 
Dermatologists to produce guidelines. Accreditation is valid for 5 
years from May 2010. More information on accreditation can be 
viewed at www.nice.org.uk/accreditation. 
For full details of our accreditation visit: 
www.nice.org.uk/accreditation. 
 
 
1.0 PURPOSE AND SCOPE 
 
The overall objective of the guidelines is to provide up-to-date, evidence-based 
recommendations for the use of Psoralen-ultraviolet A photochemotherapy (PUVA) therapy. 
The document aims to update and expand on the previous guidelines by:  
• offering an appraisal of all relevant literature since 1990, focusing on any key 
developments 
• addressing important, practical clinical questions relating to the primary guideline 
objective 
• providing guideline recommendations and, where appropriate, with some health 
economic implications 
• discussing potential developments and future directions 
 
The guideline is presented as a detailed review with highlighted recommendations for practical 
use in the clinic (see section 15.0), in addition to the production of a Patient Information Leaflet 
(PIL; available on the BAD website, www.bad.org.uk). 
 
 
2.0 STAKEHOLDER INVOLVEMENT AND PEER REVIEW 
 
The initial guideline development group (GDG) consisted of consultant dermatologists, a 
medical physicist, a nurse phototherapist and a clinical fellow in medical dermatology. The 
draft document was circulated to the BAD membership, the British Photodermatology Group 
(BPG) membership, British Dermatological Nursing Group (BDNG), National Eczema Society 
(NES), Vitiligo Society, Psoriasis Association, and Psoriasis and Psoriatic Arthritis Alliance for 
comments, which were actively considered by the GDG and peer-reviewed by the Clinical 
Standards Unit of the BAD (made up of the Therapy & Guidelines Sub-committee) prior to 
publication. 
 
 
3.0 METHODOLOGY 
 
This set of guidelines has been developed using the British Association of Dermatologists’ 
(BAD) recommended methodology1 and with reference to the Appraisal of Guidelines 
Research and Evaluation (AGREE II) instrument.2 [www.agreetrust.org] Recommendations 
were developed for implementation in the NHS using a process of considered judgment based 
on the evidence. PubMed, MEDLINE and EMBASE databases were searched up to December 
2014 for meta-analyses, randomised and non-randomised (controlled) clinical trials, case 
series, case reports, and open and cohort studies involving PUVA therapy published in the 
English language; search terms and strategies are detailed as a web appendix. Additional 
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relevant references were also isolated from citations in reviewed literature, as well as 
(independent) targeted searches carried out by co-authors. The authors screened the 
identified titles and those relevant for first-round inclusion were selected for further scrutiny. 
The abstracts for the shortlisted references were then reviewed and the full papers of relevant 
material were obtained. The structure of the guidelines published in 2000 was discussed and 
re-evaluated, and different co-authors were allocated separate sub-sections. Each co-author 
performed a detailed appraisal of the selected literature with discussions with the entire 
development group to resolve any issues, e.g. with the quality of evidence and making the 
appropriate recommendations. When considered helpful to assist with comparing study results 
and summarize data, forest plots drawn in Microsoft Excel were used,3 although no formal 
meta-analyses were performed to prepare these guidelines. All sub-sections were 
subsequently collated and edited to produce the final guidelines. 
 
 
4.0 LIMITATIONS OF THE GUIDELINE 
 
This document has been prepared on behalf of the BAD and is based on the best data 
available when the document was prepared. It is recognized that under certain conditions it 
may be necessary to deviate from the guidelines and that the results of future studies may 
require some of the recommendations herein to be changed. Failure to adhere to these 
guidelines should not necessarily be considered negligent, nor should adherence to these 
recommendations constitute a defence against a claim of negligence. Limiting the review to 
English language references was a pragmatic decision but the authors recognise this may 
exclude some important information published in other languages. 
 
 
5.0 PLANS FOR GUIDELINE REVISION 
 
The proposed revision date for this set of recommendations is scheduled for 2020; where 
necessary, important interim changes will be updated on the BAD website. 
 
 
6.0 INTRODUCTION AND HISTORY 
 
PUVA has been in use with refined psoralens since the early 1950s.4 Its use has declined 
somewhat as narrowband ultraviolet B (NB-UVB) replaced less effective broadband ultraviolet 
B (BB-UVB) sources to treat psoriasis and as NB-UVB has been proved more effective than 
PUVA to treat vitiligo.5,6 It remains an important treatment; being the first-line phototherapy for 
pityriasis rubra pilaris and plaque stage mycosis fungoides and a good second-line 
phototherapy for common chronic dermatoses including psoriasis, for which it may be more 
effective than other interventions such as the new biological therapies,7 atopic eczema and 
chronic urticaria. For phototherapy units serving small populations the availability of NB-UVB 
should be the first priority, but all larger phototherapy units should be able to offer PUVA.  
 
 
7.0 ORAL AND TOPICAL PUVA: THE DIFFERENT FORMS AVAILABLE 
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There are many different forms of PUVA. Different psoralens are available (8-
methoxypsoralen (8-MOP), 5-methoxypsoralen (5-MOP), trimethylpsoralen) and other similar 
furocoumarin compounds (such as khellin) are also used in some areas. The psoralens may 
be applied topically (as soaks, whole-body, except head and neck, in a bathwater psoralen 
liquid [bath PUVA], as cream, as gel, as lotion) and by mouth (using different formulations 
including microcrystalline tablets and liquid in capsules). Also, different ultraviolet A (UVA) 
sources are used including fluorescent BB-UVA lamps, metal halide BB-UVA lamps and 
sunlight. In the UK, oral PUVA typically involves administration of microcrystalline tablet oral 
8-MOP dosed according to estimated body surface area followed 2 hours later by exposure to 
fluorescent BB-UVA lamps.8 Usually, oral 5-MOP (which is more costly and has been less 
studied) is used if excessive nausea occurs with oral 8-MOP. 
 
 
8.0 EFFECTIVE USE OF PUVA: REVIEW OF THE EVIDENCE 
 
8.1 When should patients be treated with PUVA? 
 
For most indications PUVA is a skin-targeted immunosuppressive treatment; other 
mechanisms of action are also of likely importance. Many conditions that can be treated with 
PUVA can also be treated with NB-UVB. NB-UVB is a simpler treatment, with fewer side 
effects to consider, so PUVA is generally indicated for chronic plaque psoriasis and atopic 
eczema if NB-UVB has not been effective. In such cases PUVA is often successful: failure to 
respond adequately to NB-UVB does not predict failure of response to PUVA. For some 
indications PUVA is the first-line phototherapy (favoured over NB-UVB). These indications 
include mycosis fungoides beyond patch stage, pustular psoriasis, pompholyx, hand and foot 
eczema and, probably, adult generalised pityriasis rubra pilaris.9 
 
8.2 Selection of oral PUVA or topical PUVA (Table 1) 
 
In practice the choice of route of psoralen administration is usually based on patient 
preference. Many patients prefer oral PUVA as it involves less time in the hospital unit, but 
some choose topical PUVA, in particular to avoid the inconvenience of eye protection. 
 
9.0 PUVA FOR SPECIFIC DERMATOSES 
 
9.1 Psoriasis 
 
9.1.1 Is oral PUVA therapy more effective than topical PUVA in patients with chronic 
plaque psoriasis? 
Two randomised parallel group studies compared oral 8-MOP PUVA with 8-MOP bath 
PUVA.10,11 One prospective contemporaneous controlled (but not reported to be randomised) 
study compared oral 8-MOP PUVA with trioxsalen (trimethylpsoralen, TMP) bath PUVA12 and 
another compared oral 8-MOP PUVA with 8-MOP bath PUVA.13 None of these studies (Table 
2) detected a definite difference in efficacy between oral and bath PUVA (Figure 1), although 
one did show 18% more of the small study sample population clearing with bath than with oral 
PUVA11 (Figure 1). A recently published randomised study comparing bath 8-MOP PUVA with 
oral 8-MOP PUVA for psoriasis did not detect a difference in efficacy between these 
modalities.14 One study report included a questionnaire administered to 13 patients who had 
Commented [LE1]: All subsequent references have been 
renumbered 
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received both oral and bath PUVA. There was a roughly equal split amongst these patients in 
which form of PUVA they favoured. A recent questionnaire survey of patients referred to a UK 
phototherapy unit found a similar, roughly equal, split between patients who would choose 
bath PUVA and those who would choose oral PUVA.15 
 
Oral PUVA was not more effective than topical PUVA as a whole-body treatment for psoriasis. 
The evidence which exists from randomised controlled trials (RCTs) and prospective 
contemporaneous non-randomised controlled studies showed that bath PUVA works at least 
as well as oral PUVA. It is of value to be able to offer bath PUVA as well as oral PUVA. 
 
Recommendation: (Strength of recommendation B; level of evidence 1+) 
 
• All dermatology phototherapy units should offer bath PUVA as well as oral PUVA to 
treat psoriasis. 
 
9.1.2 Is PUVA therapy more efficacious than conventional oral systemic therapies in 
patients with chronic plaque psoriasis? 
There have been no RCTs comparing conventional oral systemic therapies with PUVA to treat 
chronic plaque psoriasis. An RCT compared PUVA with placebo (Figure 2)16 and showed a 
similar magnitude of benefit as has been shown of various conventional systemic therapies 
when compared with placebo (Figure 3).17-19 Due to differences in study methodologies, a 
meta-analysis comparing PUVA with conventional systemic therapies would not be 
appropriate. Nevertheless, the information given in these publications concerning baseline 
psoriasis severity suggests that PUVA was likely to be at least of similar efficacy in the 
relatively short term as these systemics. As the risks with PUVA are lower than the risks with 
systemic therapy,20,21 PUVA should usually be considered first. 
 
Recommendation: (Strength of recommendation B; level of evidence 1+) 
 
• PUVA should usually be offered before oral systemic therapy for patients with chronic 
plaque psoriasis that has not responded adequately to other therapies including 
narrowband UVB.  
 
9.1.3 Is PUVA therapy more efficacious than biologics in patients with chronic plaque 
psoriasis? 
This has not been assessed in any head-to-head comparative studies. However, a 
retrospective database comparison showed PUVA in the short term to be more effective than 
most biologicals in improving psoriasis by reducing a psoriasis severity score (PASI) by 75% 
(PASI 75) (Figure 4), and even more so in reducing the PASI by 90% (Figure 5).7 
 
Some national guidelines on use of biological therapy for psoriasis do not clearly indicate if 
PUVA should be used before biologics. For example, some guidelines stated that one of the 
criteria for using biological therapy was “where phototherapy and alternative standard 
systemic therapy are contraindicated or cannot be used due to the development of, or risk of 
developing, clinically important treatment related toxicity”, not clarifying whether phototherapy 
should be taken to include PUVA or not.22 
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A randomised comparative study, of adequate duration comparing PUVA with biological 
therapy would help guidance with prescribing PUVA before biological or not, taking into 
consideration the relative risks and efficacy. However, on current evidence it seems 
appropriate to continue to follow the advice in the British National Formulary23 where PUVA 
should be considered before biological therapy. 
 
Recommendation: (Strength of recommendation C; level of evidence 2+) 
 
• PUVA should always be considered before biological therapy to treat chronic plaque 
psoriasis. 
 
9.1.4 Is PUVA therapy more efficacious than NB-UVB in patients with chronic plaque 
psoriasis? 
 
Ten comparative studies of PUVA with NB-UVB to treat psoriasis have been published (Figure 
6);24-33 six of these studies were randomised,26-30,33 with the rest being contemporaneous 
controlled studies. A study by Dayal et al. is not included in Figure 6 because insufficient data 
was available in the report although it was reported that all (in both groups) reached “greater 
than 75% clearance or complete clearance”.32 One study found that PUVA was more effective 
the more severe the psoriasis was at baseline25 and another showed that PUVA remained 
more effective than NB-UVB at 6 months after completion of treatment courses.26 In most (but 
not all) comparisons involving NB-UVB three times a week there was either little difference, or 
NB-UVB was more effective, whereas in all but one of the studies comparing NB-UVB twice 
weekly with PUVA, PUVA was more effective (Figure 6). A randomised study comparing NB-
UVB twice a week with NB-UVB three times a week found 11% more patients in the latter 
group clearing;34 possibly those studies comparing twice a week NB-UVB regimens were not 
comparing optimally effective NB-UVB regimens with PUVA. Only two studies showed NB-
UVB to be significantly more effective than PUVA: both used a TMP bath PUVA regimen.27,29  
 
Overall, in the UK, PUVA appears more effective than NB-UVB for psoriasis. It may work better 
in those with more severe psoriasis, although only one study showed this as a significant 
finding. PUVA can work when NB-UVB has not worked, as found in at least one of the paired 
comparison studies. The experience of all members of the GDG is that failure to respond 
adequately (either in initial clearance or maintenance of improvement after a course) to NB-
UVB does not mean that PUVA will not prove adequate. An assessment of one region’s data 
corroborates this impression: during the 5 years (2005 to 2009 inclusive), 128 patients had a 
first course of NB-UVB followed by a first course of PUVA in Tayside. Of these PUVA courses, 
subsequent to a course of NB-UVB, 62% (70/128) were documented to achieve ‘clearance’ or 
‘minimal residual activity’ and 56% (29/52) of PUVA courses subsequent to a failed NB-UVB 
course were documented as achieving ‘clearance’ or ‘minimal residual activity’. 
 
We found no studies directly comparing PUVA with NB-UVB in children.35 It seems likely that 
the relative efficacy of these treatments will be similar to that found in adults. 
 
There are greater adverse effect concerns with PUVA than with NB-UVB; with particularly 
long-term skin cancer risks a concern when treating children for what is frequently a lifelong 
condition. Also, PUVA is more involved, requiring taking tablets, or attending for baths in a 
hospital unit. Therefore, PUVA is not a first-line phototherapy for adults, but even less so for 
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children. However, for individuals who have not adequately responded to NB-UVB it is 
appropriate to consider it, and for many children it is more appropriate than other options, 
which may include hospital admissions resulting in disruption of school and home life or 
systemic therapies with their adverse effect risks. 
 
Recommendation: (Strength of recommendation B; level of evidence 1+) 
 
• Although PUVA may occasionally be appropriate as a first-line phototherapy treatment 
for especially thick and/or extensive plaque psoriasis it should usually only be 
considered in patients with chronic plaque psoriasis if NB-UVB has not been 
adequately effective. 
 
9.2 Eczema  
We did not find any controlled studies investigating the use of PUVA in atopic eczema.  The 
findings of several uncontrolled studies have suggested that PUVA is an effective treatment 
for severe atopic eczema.36,37 A more recent randomised crossover trial found 5-MOP plus 
UVA to be superior to medium dose UVA1 in the treatment of severe atopic eczema.38 The 
authors also found that reductions in an eczema severity score were observed after only ten 
irradiations.   
 
A systematic review on the use of photo(chemo)therapy in the management of atopic eczema 
found good quality RCTs to be limited with PUVA therapy.39 
 
9.2.1 Is PUVA therapy more efficacious than narrowband UVB in patients with atopic 
eczema? 
We found no prospective trials comparing PUVA and NB-UVB. The efficacy of 8-MOP bath-
PUVA versus NB-UVB has been studied in a half-side comparison study.40 The authors of this 
small study concluded that both regimens were not detectably different in efficacy. In the 
absence of strong evidence favouring PUVA, NB-UVB should be the first-line phototherapy 
for atopic eczema as a simpler and safer intervention. 
 
Recommendation: (Strength of recommendation D; level of evidence 3) 
 
• PUVA should be considered in patients with atopic eczema only if NB-UVB has not 
been adequately effective. 
 
9.2.2 Is PUVA therapy more efficacious than conventional oral systemic therapies in 
patients with atopic eczema? 
There were no direct comparative trials comparing systemic agents with PUVA in patients with 
atopic eczema. 
 
9.2.3 Is PUVA therapy more efficacious than narrowband UVB in children (younger than 
16) with eczema? 
Whilst there were several retrospective studies showing efficacy of PUVA in children with 
atopic eczema, there were no direct comparative studies comparing PUVA with NB-UVB in 
children. A large study of 113 Japanese patients with severe atopic eczema treated with oral 
PUVA, which included 18 patients aged 12 to 19 years, reported that the majority of patients 
improved with PUVA,36 although only 31 subjects were scored for severity. The efficacy of 
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bath PUVA therapy in severe cases of atopic dermatitis (AD) in adults has been studied in 
children over 12 years.41 This small study of 30 subjects reported patient evaluations with an 
overall patient satisfaction score of 8.8 on a scale of 0 to 10.  
 
The most convincing evidence for the use of PUVA in children with atopic eczema came from 
a report by Sheehan et al. who described 32 of 39 children able to achieve remission.42  Similar 
results have been reported for the use of UVB in children with atopic eczema.43 
 
9.3 Cutaneous T cell lymphoma 
PUVA remains a major therapeutic modality in the treatment of cutaneous T cell lymphoma 
(CTCL). Its use is in the treatment of the commonest form of CTCL, mycosis fungoides (MF), 
where it remains the major therapy for plaque-stage disease. PUVA phototoxicity has been 
shown to target selectively neoplastic T lymphocytes in the skin.44-48  
 
9.3.1 How does PUVA compare to other types of phototherapy in CTCL? 
 
a. Narrowband UVB (TL-01) compared to PUVA 
There are no double-blinded, controlled comparison trials of PUVA versus NB-UVB for 
the treatment of early stage CTCL, and most data is from retrospective studies.  These  
show similar remission rates of 50% to 81% for UVB, and 64% to 71% for PUVA [Refer 
to online journal for more details]. 
 
b. Other types of phototherapy 
 
i. Broadband UVB (BB-UVB): 
There are no comparative studies of BB-UVB against PUVA in CTCL. Like NB-
UVB, the role of BB-UVB in CTCL appears to be in early stage disease.49,50 
 
ii. UVA-1 
There are no comparative studies of UVA1 versus PUVA. There is limited data 
regarding UVA1 therapy in CTCL, and this suggests that it potentially may be a 
useful treatment in patch-stage disease51 and perhaps in more advanced disease 
as well.52  
 
Recommendation: (Strength of recommendation D; level of evidence 3) 
 
• For patch-stage CTCL, NB-UVB is as effective as PUVA and is the treatment of choice.  
 
Recommendation: (Strength of recommendation D; level of evidence 4) 
 
• For plaque-stage CTCL, PUVA is the treatment of choice. 
 
9.3.2 When should PUVA be used in CTCL? 
PUVA is very effective in clearing lesions of early-stage CTCL, i.e. patches and thin plaques. 
Its effect on infiltrative thick lesions and tumours is more controversial.53 Since patch stage 
disease is so responsive to NB-UVB, PUVA’s role is primarily in the treatment of plaque-stage 
disease. However, one must be aware and use caution in this setting, knowing that there may 
be an increased risk of other skin tumours if immunosuppressive agents are required later in 
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the disease process.54 It is not always possible to predict in advance who might require 
systemic immunosuppressive therapies later and progressing to next-line therapies earlier 
rather than PUVA is often not appropriate. The issues should be fully discussed with patients. 
 
For more details of PUVA studies in CTCL, please refer to the online journal. 
 
Flexural sites (‘sanctuary sites’) often fail to respond completely - in both patch and plaque 
stages - and the duration of response varies.55 
 
Trial evidence of the role of PUVA in late-stage disease is more limited but nevertheless 
suggestive that PUVA, as a monotherapy, is not an effective therapy in late-stage disease.  
 
Treatment schedules vary in studies of PUVA from twice to four times a week with varied 
increment protocols.  In the UK, commonly used schedules are two- to three-times-a-week 
treatments until disease clearance or best partial response.55 Unlike in most other conditions 
treated with phototherapy, maintenance therapy to prevent disease relapse in patients with 
quickly recurrent disease is still common practice.56 There is, however, no consensus on this 
(and a trial comparing maintenance versus no maintenance in PUVA for MF is ongoing 
[Clinical Trials Registry, NCT01686594]) and the benefits of maintenance therapy are still 
uncertain. Whittaker et al. concluded that maintenance PUVA therapy should be avoided and 
the cumulative lifetime PUVA exposure should be limited (1200 J/cm2 of UVA and/or 250 
sessions) (Whittaker et al. BAD skin lymphoma guidelines. In  preparation)  
 
Recommendation: (Strength of recommendation B; level of evidence 1+) 
 
• PUVA is the first-line treatment for plaque-stage MF.  
 
Recommendation: (Strength of recommendation D(GPP); level of evidence 4) 
 
• Maintenance therapy may be considered to prevent relapse in quickly-recurrent 
disease. 
 
9.3.3 When should PUVA be used with other therapies? 
In practice, PUVA is often used with other therapies rather than as monotherapy, as follows 
[Refer to online journal for more details]: 
 
• PUVA with interferon   
• PUVA with retinoids and rexinoids 
• PUVA following Total Skin Electron Beam therapy (TSEB) 
 
Recommendation: (Strength of recommendation B; level of evidence 1+) 
 
• In the treatment of early-stage CTCL, combination therapy with PUVA and interferon 
or retinoids/rexinoids should be considered, if the response to monotherapy is slow. 
  
 
9.4 Vitiligo 
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9.4.1 Is PUVA therapy more efficacious than narrowband UVB in patients with vitiligo? 
No; NB-UVB is at least as effective as PUVA in treating vitiligo (Figure 7).6,57,58 Also, the match 
of repigmentation to normal skin colour is better with NB-UVB than with PUVA,6 and NB-UVB 
is more effective in inducing repigmentation in unstable vitiligo than is PUVA.58,59 These 
studies involved widespread vitiligo vulgaris; there is no available good quality evidence 
comparing PUVA and NB-UVB for other patterns of vitiligo, such as segmental vitiligo.  
 
Recommendation: (Strength of recommendation A; level of evidence 1+) 
 
• PUVA should only be considered for widespread vitiligo if NB-UVB has not shown to 
be adequately effective. 
 
9.5 Photodermatoses 
 
Due to the relative rarity of some idiopathic photodermatoses and paucity of evidence in this 
area, the literature search was extended to include all papers from 1966. Both oral and topical 
PUVA have been reported to be used in the following idiopathic photodermatoses: 
polymorphic light eruption (PLE), chronic actinic dermatitis (CAD), solar urticaria (SU), 
erythropoietic protoporphyria (EPP), and actinic prurigo (AP). Most papers were found in PLE 
(n = 15), followed by SU (n = 8), CAD (n = 7), AP (n = 2) and EPP (n = 2). 
 
9.5.1 In the treatment of photodermatoses, what is the efficacy and safety of PUVA 
compared to UVB?  
 
a. PLE 
In PLE, the reported efficacy of PUVA was 65% to 100% photoprotection rate.60-71 There 
were five comparative studies with UVB,60,61,63,65,66 including two RCTs.63,65    
 
The only RCT comparing PUVA with NB-UVB did not detect any significant difference 
in efficacy. In this trial, 12 patients treated with oral 5-MOP or 8-MOP PUVA were 
compared with 13 patients treated with UVB and placebo tablets [first dose was 70% 
minimal phototoxic dose (MPD)/minimal erythema dose (MED); 20% increments; thrice 
weekly UV exposures for 5 weeks]. The study found no significant differences between 
the two forms of phototherapy in reducing the number of episodes of PLE or restriction 
of outdoor activity.63 
 
There were two studies that compared the efficacy of PUVA with BB-UVB.65,66 In an 
RCT, oral 8-MOP PUVA (n = 13) was compared with BB-UVB plus placebo tablets (n = 
13) and low-dose UVA plus placebo tablets (n = 12).65 Using self-assessment of 
treatment efficacy, 92% of patients considered PUVA successful compared with 62% 
with BB-UVB. These findings were supported by Addo et al., who reported complete 
remission in 89% of patients treated with PUVA compared with 69% treated with BB-
UVB.66  
 
Man et al. reported a 10-year retrospective review of 170 patients with moderate-to-
severe PLE who attended for PUVA and/or UVB phototherapy.60 Eight patients received 
PUVA, 128 NB-UVB, five BB-UVB and 29 patients who failed to respond satisfactorily 
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to NB-UVB were given PUVA the following year. The patients were followed up in 
autumn or the following spring and self-assessments were made of the severity and 
frequency of PLE episodes. Two hundred and eighty-one courses of UVB and 99 
courses of PUVA were evaluated. At follow-up, 88% of those who received PUVA and 
89% who received UVB reported good or moderate improvement, and of the 29 who 
received both PUVA and NB-UVB, 12 favoured PUVA, four preferred NB-UVB, and five 
responded equally well.60  
 
Mastalier et al. presented 14-year retrospective data on 79 patients treated with 
phototherapy; 17 patients with oral 5-MOP or topical 8-MOP PUVA, 56 with BB-UVB, 
and six with UVA alone. The patients were assessed on the first summer after 
phototherapy for prevention of PLE episodes. The photoprotection rate was 
complete/partial remission in 65% for PUVA, 82% for BB-UVB, and 83% for UVA. 
However, the authors acknowledged that PUVA was given to patients with more severe 
symptoms, while BB-UVB and UVA alone were given to patients with milder symptoms.61 
 
The latter two studies were retrospective chart review studies, with smaller numbers of 
patients receiving PUVA compared to UVB; moreover, patients who had more severe 
PLE, or who had previously failed UVB tended to receive PUVA.60,61 
 
i. Safety of PUVA compared to UVB in PLE 
There is an inherent risk of provoking the underlying condition in treating any 
photodermatosis. There was limited comparative data between the two forms of 
phototherapy to ascertain which form is more likely to provoke the eruption. 
Pooling the incidence of adverse events from the small number of PLE studies, 
the side effects of rash provocation, erythema and pruritus were found to be 
common in both forms of phototherapy, though commoner with UVB than with 
PUVA (Table 3). However, as the number of patients in each cohort was small 
and the severity of the adverse events not directly comparable, the overall 
percentages should be regarded with caution.  
 
In the treatment of PLE, the side effects of rash provocation, erythema and pruritus 
were found to be common in both forms of phototherapy. There was no 
appreciable difference in the efficacy of PUVA and UVB. 
 
b. Photodermatoses other than PLE 
No comparative studies with UVB were identified for the other photodermatoses. 
 
9.5.2 When should PUVA be used in preference to other therapies for 
photodermatoses?  
Photodermatoses are chronic conditions requiring ongoing treatment. Photoprotective 
measures and symptomatic treatment may be adequate in milder cases; however, in more 
severely affected patients, second-line treatments are often required. First-line treatment may 
include topical corticosteroids, antihistamines, beta-carotene (for EPP) and is not within the 
scope of this guideline. Second-line treatment may include phototherapy.  NB-UVB is 
generally considered before PUVA, because it has the following advantages: lower risk of 
photocarcinogenesis, no risk of nausea or other side effects with ingestion of MOP and 
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increased convenience as there is no need for taking tablets or using eye protection post-
treatment.  
 
a. PLE  
There is good evidence of efficacy with UVB as compared with PUVA.63 There are no 
other direct comparative studies with other modalities of treatment, which include 
systemic corticosteroid,72 azathioprine,73 ciclosporin,74 hydroxchloroquine,75,76 beta-
carotene,77-79 nicotinamide,80,81 omega-3 fatty acids,82 antioxidants83-85 and E. coli 
infiltrate.86 Systemic corticosteroid has been demonstrated to reduce the severity of PLE 
when used as a short course on sunny holidays.87 Systemic immunosuppression is 
effective in a small number of case reports. Efficacy of treatment with 
hydroxychloroquine, beta-carotene, nicotinamide, omega-3 fatty acids, antioxidants, 
and E. coli infiltrate has not been well established in RCT. 
 
Recommendation: (Strength of recommendation D; level of evidence 4) 
 
• In the treatment of PLE, NB-UVB should be considered before PUVA. However, PUVA 
should be considered if NB-UVB has failed, or has previously triggered the eruption, 
or if there are other practical issues. PUVA should be considered before other systemic 
treatments. 
 
b. Chronic actinic dermatitis (CAD) 
 
We found no comparative studies using PUVA in the treatment of CAD. There are a 
limited number of case reports and small case series reporting the use of PUVA in 
CAD.88-94 These studies include the use of PUVA under cover with topical or oral 
corticosteroid, and concomitant use of ciclosporin (cyclosporin) and mycophenolate 
mofetil [Refer to online journal for more details]. 
 
One tertiary referral unit in the UK routinely treats CAD patients with PUVA with success 
(personal communication, Garibaldinos T, Guy’s and St Thomas’ Hospital, London) . 
Prednisolone (20 to 30 mg) is taken on the day of phototherapy; small-dose increments 
of 0.05 J/cm2 is given with each UVA-exposure; the course is given three times a week, 
then stepped down to twice weekly and then once weekly. Inpatient supervision is not 
generally required. 
 
Recommendation: (Strength of recommendation D; level of evidence 4) 
 
• In the treatment of CAD, PUVA therapy should be considered in a specialist unit 
experienced with managing this disease, with full knowledge of the individual patient’s 
action spectrum. Special precautions including inpatient supervision and topical/oral 
corticosteroid cover may be required. 
 
c. Idiopathic solar urticaria (SU) 
We found no comparative studies with PUVA in the treatment of SU.  
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PUVA has been used in small case series as monotherapy (n = 4; n = 6),66,95 in 
combination with intravenous immunoglobulins (single case reports)96 and with 
plasmapheresis.97,98 [Refer to online journal for more details] 
 
Antihistamines are regarded as the standard therapy in SU (other than photoprotection); 
RCTs are not available in SU itself and it is reported that a substantial proportion of 
these patients receive only modest benefit.99-101 High-dose H1 antihistamines are 
frequently prescribed, in line with published research and recommendations made in 
general for other chronic urticarias.102 
 
NB-UVB has also been reported to be helpful in SU (Calzavara-Pinton et al. [n = 39], 
Wolf et al. [n = 1], Collins et al. [n = 1]).103-105 [Refer to online journal for more details] 
There are no comparative trials between NB-UVB and PUVA.  
 
There was limited evidence from small case series on the use of UVA, either 
administered on its own,106-108 or as pre-PUVA de-sensitisation.109 This has been used 
in patients who have very low MUD for UVA, where PUVA was thought to be unsafe 
[Refer to online journal for more details] 
 
Recommendation: (Strength of recommendation D; level of evidence 4) 
 
• In the management of SU (after full assessment including definition of the action 
spectrum), PUVA can be considered. The treatment should be carried out with full 
knowledge of the patient’s action spectrum, in a specialist unit experienced with 
managing this disease. 
 
d. EPP 
We did not find any comparative trials with PUVA in the treatment of EPP.  
 
There was limited evidence in the use of PUVA in EPP.110,111  UVB has been reported 
in small open studies to be effective in EPP (n = 6; n = 1; n = 12).105,112,113 [Refer to online 
journal for more details] 
 
PUVA cannot currently be recommended in the treatment of EPP due to lack of evidence 
and comparative trials with beta-carotene or UVB, and the long-term risks associated 
with the need for annual treatment on a lifelong basis. 
 
Recommendation: (Strength of recommendation D; level of evidence 4) 
 
• PUVA is rarely appropriate in EPP in which NB-UVB is the phototherapy of first choice. 
 
e. AP 
We did not find any comparative trials of thalidomide or immunosuppressants with PUVA 
in the treatment of AP. 
 
There was limited evidence of the use of PUVA in AP. UVB has been reported, in a small 
open study, to be effective in AP (n = 6).105 [Refer to online journal for more details]. 
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Recommendation: (Strength of recommendation D; level of evidence 4) 
 
• NB-UVB may be a safer therapeutic option in terms of phototherapy-associated 
carcinogenic risk in patients with AP, particularly in children, and should be considered 
before PUVA. 
 
9.5.3 What special precautions should be undertaken during PUVA therapy of 
photodermatoses?  
Photodermatoses run a high risk of provocation with the different forms of phototherapy. 
Special precautions are required and are described below for the better-reported 
photodermatoses PLE, CAD and SU. PUVA is usually administered in early spring in 
temperate countries. The benefit conferred by phototherapy is diminished or lost several 
weeks post-phototherapy, and post-treatment advice generally includes continued natural 
sunlight exposure, if tolerable on an individual basis, to keep their resistance to provocation 
for the rest of summer. As PUVA generally needs to be repeated, the longer-term risk of skin 
carcinogenesis need to be weighed against the therapeutic benefit and annual desensitization 
is not usually recommended.  
 
a. PLE 
The regimens vary between phototherapy centres; most administer 8-MOP, although 5-
MOP, oral and bath TMP, have all been used.60-71 In most of these studies, 8-MOP PUVA 
was given three times a week for 12 to 20 treatments. Currently in the UK, a twice-
weekly regimen is standard. There are no studies comparing the efficacy and safety of 
twice- and thrice-weekly regimens. 
 
Although there were no studies on the timing of PUVA therapy during the year, this is 
likely to be an important consideration particularly in temperate climes. If administered 
too early in the year, the photoprotective effect may have subsided by mid-summer; 
administered too late, the patient may have already suffered an eruption and PUVA may 
increase the risk of provocation or further aggravation. 
 
The risk of provoking PLE is high, particularly with the first few PUVA exposures. At least 
one episode was induced during 12% to 50% of PUVA treatment courses,60,62-65,68,69,114 
which is a little lower than the rates with UVB of 48% to 62%.60,63 There is evidence that 
PUVA is as likely as UVB to cause provocation of PLE. Provocation episodes can be 
managed with potent topical steroid and subsequently lower dose increments, omitting 
one or two treatments if particularly severe.60,62,63,68,69 To prevent provocation, one group 
administered oral prednisolone (40 to 50 mg) for the first 2 weeks of phototherapy,67 
whilst another reported routine prophylactic application of a potent topical steroid after 
each exposure in UVB phototherapy.60  
 
Pruritus was also reported in 18% to 33% patients63,64 with one group managing this with 
oral corticosteroid.64  
 
Post-treatment advice generally includes continued natural sunlight exposure, ranging 
from 2 hours weekly65 to ‘cautious exposure, with sunscreens for extended outdoor 
stay’,60 to ‘expose freely to sun’.67,70 
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b. CAD 
PUVA phototherapy is generally undertaken under close supervision under cover of 
topical or systemic corticosteroid, as discussed above.90,91,93,94 Maintenance treatment 
may be required. Annual repeated courses can be considered but the benefit needs to 
be balanced against the long-term risk of skin carcinogenicity. 
 
c. SU 
Treatment of SU with phototherapy can potentially result in provocation, syncope, and 
anaphylaxis. UVA is often, but not always, a wavelength where there is sensitivity in this 
disease. The choice of PUVA for SU as a therapy, and the protocol used, will be 
governed by the action spectrum as determined by monochromator phototesting. 
 
Thus, it is important to determine both the action spectrum of the disorder, in a 
specialized phototesting unit, and the MUD before starting phototherapy, preferably with 
the UV source to be used for treatment. The initiating dose should be lower than the 
MUD. In patients with a very low MUD, UVA alone,106-108 or pre-PUVA UVA has been 
used.109 The amount of photoprotection will subside, and maintenance treatment with 
PUVA or UVA has been reported.  
 
 
 
Key points: 
 
• When using prophylactic phototherapy to treat photodermatoses, the 
risk of rash provocation is high. The use of topical/oral corticosteroids 
may be used prophylactically or therapeutically in PLE or CAD. 
 
• Phototherapy may be given in spring, or before a sunny holiday, before 
expected increased natural UV exposure. 
 
• Particularly with CAD and SU, the action spectrum should be determined 
prior to commencement of phototherapy; PUVA should only be carried 
out in an experienced specialized unit. 
 
• With AP and EPP, UVB should be considered before PUVA. 
 
• Post-treatment advice of cautious, continued sunlight exposure should 
be given to maintain the photoprotective effect, but this is dependent on 
individual tolerance and photoprotection is still needed in very sunny 
conditions. 
 
 
9.6 Hand and foot dermatoses 
 
Local PUVA, using both oral and topical psoralens, has been widely used to treat hand and 
foot dermatoses over the past 25 years and is generally considered an effective therapy. Oral 
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psoralen is favoured by some patients for convenience (less time spent in a hospital treatment 
unit) and because there are lower risks of phototoxic reactions. Topical psoralen is  
favoured by other patients who prefer not to take oral medication and to avoid the potential 
risks of systemic side effects and/or drug interactions. In addition, the use of eye protection 
outside the UV irradiation period is not required. Different forms of topical psoralen are in use 
including soaks, paint, cream, ointment, emulsion and gel. Treatment regimens also vary not 
only with regard to methods of psoralen application but in the time interval between psoralen 
application and UVA irradiation. It has previously been shown in a small study that, in 
unaffected skin of the palms and soles, there is a lag time of approximately 40 minutes 
between soaking in psoralen solution and maximum UVA sensitivity in the palmar and plantar 
skin of healthy volunteers.115 As a result of this, and earlier reports that suggested efficacy in 
the hand and foot dermatoses of topical psoralens with a 1- to 2-hour delay between psoralen 
application and UVA exposure but no efficacy in studies with psoralen application immediately 
before UVA exposure, previous UK guidelines have recommended a delay of at least 30 
minutes between immersion and irradiation.116 
    
The hand and foot dermatoses comprise three main conditions: eczema, psoriasis and 
palmoplantar pustulosis.   
 
9.6.1 What is the efficacy of PUVA therapy in patients with hand and foot dermatoses 
compared to placebo or other active treatments? 
 
a. Palmoplantar eczema 
Oral PUVA vs UVB: A  prospective contemporaneous controlled study (n = 35)117 
showed both treatments to be effective but oral PUVA was superior to UVB, although 
relapse rate was high. A subsequent smaller study (n = 20) carried out by the same 
group using a similar design showed similar results.118  
 
Oral PUVA alone: Uncontrolled studies with oral PUVA have shown significant 
improvement or clearance in 81% to 86% of patients with hand and foot eczema,119,120 
with similar good results in smaller case series.121,122  
 
Topical PUVA alone: Uncontrolled studies of topical PUVA have suggested this might 
be effective treatment with clearance or considerable improvement reported in 58% to 
81% of dyshidrotic eczema and 50% to 67% of hyperkeratotic eczema.123-134 However, 
evidence from comparative studies was less convincing. A left-right, within-patient study 
(n = 15) with 8-MOP paint versus placebo in dyshidrotic eczema found no difference 
between the two groups, and no patient achieved clearance.135 The lack of efficacy was 
supported by a small controlled study (n = 6) with 20% 8-MOP gel in which no patient 
cleared.136 
 
Topical PUVA vs UVB, UVA1, superficial X-ray therapy, and combination therapy of 
topical PUVA and iontophoresis: [Refer to online journal for more details] Evidence from 
RCTs and prospective contemporaneous controlled studies has not demonstrated any 
difference in efficacy . 
 
In summary, in hand eczema, evidence from two prospective contemporaneous 
controlled studies have shown PUVA using oral psoralen to be effective and superior to 
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UVB. Evidence from RCTs and prospective contemporaneous controlled studies has 
not demonstrated topical PUVA to be more effective than placebo, UVB, UVA1 or 
superficial X-ray therapy. However, some uncontrolled studies have shown topical 
PUVA to be associated with good degrees of improvement. All comparative studies 
lacked the power to detect what might still be important differences between treatments. 
 
Recommendation: (Strength of recommendation B; level of evidence 2++) 
 
• PUVA, using oral psoralen should be considered as a treatment for hand and 
foot eczema. Although the evidence for topical PUVA in palmoplantar eczema is 
weak, lack of proof of efficacy does not prove no efficacy and in open discussion 
with patients, it will sometimes be appropriate to consider topical PUVA. 
 
b. Palmoplantar psoriasis 
We found no comparative studies comparing oral PUVA to placebo or other active 
treatments, though a small retrospective study (n = 12)137 and case series (n = 5)121  
report improvement or clearance.  
 
Oral PUVA vs NB-UVB: A large retrospective study (n = 92) concluded oral PUVA and 
NB-UVB were equally effective. However, assessment and outcome measures were 
unclear and no statistical analysis was carried out.138 
 
Topical PUVA alone: Uncontrolled studies have reported clearance or significant 
improvement occurring in 58% to 87% of patients treated with topical psoralen.123,126-
128,130,131,139-142  
 
Topical PUVA vs UVA: In a randomised, left-right, within-patient study in patients with 
hand and foot dermatoses (psoriasis n = 11), topical PUVA (20% 8-MOP gel) was 
suggested to be more effective overall compared to UVA, but the results were not 
analyzed separately according to the different dermatoses investigated.136 No patient 
was reported as being cleared in either group.  
 
Topical PUVA vs 308 UVB excimer laser, and NB-UVB: Refer to online journal for more 
details. The authors of a Cochrane systematic review of NB-UVB phototherapy versus 
BB-UVB or PUVA for psoriasis identified only one study for the indication and concluded 
no significant difference between treatments.143  
 
In summary, for palmoplantar psoriasis there is some randomised study evidence for 
topical PUVA, however, these studies were under-powered. Oral PUVA for this 
indication has not been studied adequately. 
 
Recommendations: (Strength of Recommendation C; Level of Evidence 2++)  
 
• PUVA using topical or oral psoralen should be considered as a treatment for 
palmoplantar psoriasis.  
 
c. Palmoplantar pustulosis  
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Oral PUVA vs no treatment: Oral PUVA has been compared with no treatment in a 
randomised, within-patient study (n = 22).144 This showed improvement in 100% of 
PUVA-treated sites compared with 59% of untreated sites, with 55% and 0% clearance, 
respectively. In a prospective contemporaneous controlled study (n = 14), improvement 
was recorded in 64% with oral PUVA and 14% with no treatment.145 The clearance rate 
was 21% and 0%, respectively. 
 
Topical PUVA vs placebo: In a double-blinded, randomised, left-right, within-patient 
study (n = 27),146 there was no difference in improvement with topical PUVA compared 
to placebo. The lack of efficacy of topical PUVA was further supported by smaller 
randomised studies (n = 10, n = 5)136,147 with clearance rate of only 0% to 10%. 
 
PUVA vs oral retinoids: Two RCTs have compared PUVA to oral retinoids. One study (n 
= 84) compared two forms of topical PUVA, oral PUVA and etretinate.148 A total of 12% 
(4/33) treated with topical methoxsalen cream cleared compared with 70% (14/20) in the 
etretinate group. None cleared in the oral PUVA and trioxsalen soak group. This 
suggests etretinate to be more efficacious, but response to PUVA, and in particular oral 
PUVA, was much lower than in other published studies. Another study comparing oral 
PUVA to etretinate showed clearance in 21% (3/12) with PUVA versus 17% (3/18) with 
etretinate.145  
 
The authors of a Cochrane systematic review of interventions for palmoplantar 
pustulosis, which included the controlled studies detailed above, concluded that oral 
PUVA is an effective intervention for this indication, although the combination of retinoids 
plus oral PUVA is more effective. No proven benefit has been demonstrated with topical 
PUVA and no definite benefit of retinoid as a monotherapy over PUVA was 
established.149 
 
Recommendations: (Strength of Recommendation C; Level of Evidence 2++)  
 
• Oral PUVA should be considered as a treatment for palmoplantar pustulosis. 
 
9.6.2 What is the efficacy of oral PUVA compared to topical PUVA therapy in patients 
with hand and foot dermatoses? 
 
a. Palmoplantar eczema 
Two RCTs have compared oral and topical PUVA. Van Coevorden et al. performed an 
open-label RCT (n = 158) comparing oral methoxsalen (as safer for home use than 
topical psoralens) using a home UVA unit with topical PUVA using trioxsalen soaks in a 
hospital setting over a 10-week period.150 The mean hand eczema scores showed a 
significant reduction of 41% in the oral PUVA group compared with 31% in the topical 
PUVA group, with no statistically significant difference between the two groups. This 
improvement was maintained at 8-week follow-up. 
 
A small RCT compared oral 8-MOP versus 8-MOP soak in dyshidrotic eczema (n =15) 
and hyperkeratotic eczema (n = 12). This study did not detect a difference in therapeutic 
efficacy, and that dyshidrotic eczema improved to a greater extent compared to 
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hyperkeratotic eczema, however, the study was under-powered and does not justify 
these conclusions.151 
 
b. Palmoplantar psoriasis 
A retrospective review by Hawk et al. of oral and topical 8-MOP PUVA in the treatment 
of patients with hand and foot dermatoses included 18 patients with psoriasis.152 Fifty 
50% (7/14) of patients who received topical PUVA and 50% (2/4) oral PUVA cleared. A 
small, within-patient, randomised, right-left comparison study compared PUVA using 
oral oxsoralen versus PUVA using 8-MOP soaks in patients with palmoplantar 
dermatoses but included only three patients with psoriasis. Oral PUVA was reported to 
be more effective.153  
 
c. Palmoplantar pustulosis 
Hawk et al.’s retrospective review which included 15 patients with palmoplantar 
pustulosis showed clearance in 67% (4/6) with oral 8-MOP and 33% (3/9) with topical 8-
MOP emulsion.152 
 
A small, right-left, within-patient comparative study of oral oxsoralen versus 8-MOP 
soaks in patients with hand and foot dermatoses included five patients with pustulosis. 
Oral PUVA was reported to be more effective.153  
 
Lassus et al.’s RCT of two forms of topical and oral PUVA showed clearance rate of 8% 
(4/51) with topical PUVA compared with 0% (0/13) oral PUVA.148 PUVA as a whole was 
disappointing in that study and no difference between the methods of delivering it was 
detected. A Cochrane review of interventions for palmoplantar pustulosis found only one 
direct comparison of topical with oral PUVA for this indication.149 
 
Recommendation: (Strength of recommendation D(GPP); Level of evidence 4) 
 
• Oral PUVA should usually be considered as the first-line PUVA treatment for 
patients with palmoplantar dermatoses. 
 
9.6.3 What is the efficacy of PUVA therapy alone compared to PUVA and adjuvant 
therapies in the hand and foot dermatoses? 
 
a. Palmoplantar eczema 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
For foot eczema, topical PUVA has been compared in a randomised trial to topical PUVA 
combined with iontophoresis over an 8-week treatment period and at follow-up 8 weeks 
later. There was no significant difference in eczema and DLQI scores.154  
 
b. Palmoplantar psoriasis 
There was only one RCT comparing combination therapy with oral PUVA and etretinate 
versus PUVA and placebo but this included only three patients with psoriasis.155 No 
other relevant studies were identified. 
 
c. Palmoplantar pustulosis  
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Three RCTs examined combination therapy with oral PUVA and retinoids compared to 
PUVA alone. Rosen et al.’s RCT showed clearance in 61% (14/23) with combination 
therapy and 21% (3/14) with PUVA alone.145 A further RCT comparing oral PUVA-
etretinate versus oral PUVA alone showed clearance of 100% (8/8) and 44% (4/9), 
respectively.155 An RCT using 8-MOP PUVA lotion found 60% (6/10) clearing with topical 
PUVA-etretinate compared with 10% (1/10) with topical PUVA alone.147  
 
A Cochrane review of the interventions for palmoplantar pustulosis concluded there was 
evidence for an increased efficacy of retinoids combined with PUVA compared to PUVA 
used alone.149 
 
Recommendation: (Strength of Recommendation 1+; Level of Evidence A)  
 
• Unless there are contraindications, the combination of oral PUVA with oral 
retinoids should be considered as a treatment for palmoplantar pustulosis. 
 
 
10.0 ADVERSE REACTIONS TO PUVA  
  
10.1 Acute  
 
10.1.1 Incidence of acute adverse events [Refer to online journal for full discussion]. 
Both systemic and topical PUVA are generally well tolerated and the acute adverse effects of 
PUVA are reasonably well documented. The commonest adverse effects are erythema and 
pruritus, and nausea associated with oral PUVA.115,156 In early studies of oral PUVA, reported 
acute adverse events were uncommon, temporary and generally mild. Melski et al. analyzed 
the adverse events from 41,000 oral PUVA treatments given to 1,308 patients.157 The 
incidence of adverse events was: erythema 9.8%, pruritus 14%, nausea 3.2%, headaches 
2%, dizziness 1.5%. In later large series (n = 3175), the incidence of adverse events reported 
were higher: erythema 32.4%, pruritus 25.6%, nausea 13.5%, headaches 2%, Köbner 
reaction in psoriasis 2%.158,159 PUVA treatment was interrupted due to erythema in 6.8%, and 
only uncommonly discontinued. Nausea with 8-MOP is a relatively common occurrence but 
not with 5-MOP160  and rarely requires discontinuation of treatment. 
 
a. Erythema  
Studies of the time course of PUVA erythema following both oral and topical PUVA 
indicate erythema peaking at 96 hours or later in the majority of subjects. Oral 5-MOP 
PUVA has a similar time course to that of 8-MOP.161  In practice, many centres use an 
MPD assessment time of 72 hours and no studies have been undertaken to evaluate 
whether there are differences in efficacy or adverse effects between treatment regimens 
based on a 72-hour versus 96-hour MPD assessment. Most UK centres use a twice-
weekly regimen for both oral and topical PUVA. 
 
The UVA dose should be delivered within 10 minutes after an 8-MOP bath as 
photosensitivity reduces quickly, although there may be a more prolonged effect over 
40 minutes if palmar and plantar skin are being treated.116,162 The temperature of the 
bath for PUVA delivery is also important, with photosensitisation being optimal at 37°C 
and reduced at lower temperatures.163  
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Unusual patterns of erythema and burning have been reported, particularly with TMP 
bath PUVA due to the powder formulation of TMP and the variable distribution within the 
bath water as it forms a micro-crystallized suspension.164 Frank blisters can also occur 
either due to over-exposure to UVA or psoralen dose, for example, as seen if patients 
stand in a particular way in the cabinet.165 Particular care is needed in patients with 
vitiligo.166,167, 
 
Thus, depending on the methods for reporting erythema, incidence of PUVA erythema 
during treatment is between 10% and 32%, requiring treatment interruption in between 
1% to 7% of cases. Patients of lighter skin phototype and those treated with more 
frequent treatment regimens are at greatest risk of developing erythema during 
treatment.  Early recognition of cumulative erythema is important and omission of 
treatment until this has resolved and adjustment of dose increments may be required. 
Topical emollients and steroids may offer symptomatic relief. 
 
b. Pruritus 
There seems to be a similar incidence of pruritus following oral and bath PUVA occurring 
in 10% to 40% of patients.115,157,159 The incidence of pruritus is reported to be lower with 
5-MOP (43.6%) compared with 8-MOP (71.8%).164 There do not appear to be specific 
predictors for the likelihood of this adverse effect occurring.   
 
c. Nausea  
Nausea is relatively common, occurring in about 3% to 13% of patients.157,159,168 This 
can be helped by taking the psoralen with a light meal or using an antiemetic. If nausea 
is significant then 5-MOP or topical psoralen can be used.168 The incidence of nausea 
was reported to be much lower with 5-MOP (7.7%) compared with 8-MOP (51%) in one 
study.164  
 
d. Induction of photodermatoses 
Precipitation or aggravation of photodermatoses which are associated with abnormal 
UVA photosensitivity can occur with PUVA, with reports of CAD and PLE exacerbation 
having been observed.63,169 The rate of inducing PLE was estimated to be 50% 
compared with 62% with NB-UVB in one study.63 Theoretically, exacerbation or 
induction of lupus can occur, and there are case reports of the coincidence of PUVA 
with the development of lupus.170-172 
 
e. Drug phototoxicity 
Drug phototoxicity in general is not a major problem because of the overwhelming effect 
of psoralen photosensitisation, and as long as MPD assessment is performed on the 
patient’s drug regimen, this can be largely avoided.168 However, pseudoporphyria can 
occur, as with some of the other phototoxic drugs such as the fluoroquinolones, non-
steroidals, tetracyclines and diuretics, and is more likely to occur after minor trauma and 
on acral sites. Furthermore, enhancement of PUVA phototoxicity has been reported after 
ingestion of celery and vegetable broths during PUVA therapy173 and after taking 
Rutaceae extracts and celery soup.174 Reported phototoxicity rates seem to be similar 
for oral and bath 8-MOP PUVA,115 although clinical experience suggests that severe 
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phototoxic reactions are more likely with bath PUVA. In general, avoiding psoralen-
containing plants for at least 2 hours before treatment is advised. 
 
Systemic psoralen can interfere with liver metabolism, which results in many potential 
drug interactions. Psoralens cause liver enzyme inhibition which in turn causes a 
potential serum increase of the following: warfarin, anticholinergics, antipsychotics, 
NSAID, theophylline, caffeine; more frequent monitoring is advised if a patient is on 
warfarin. The effects of caffeine are augmented by PUVA,175-177 and can occasionally 
cause headaches and ‘jitteriness’ on treatment days. Advice to reduce caffeinated 
beverage intake on these days may be required. Systemic psoralen can also cause liver 
enzyme induction which may reduce serum concentration of: ciclosporin, chemotherapy 
agents, azole antifungals, macrolides, tricyclics, antidepressants and antipsychotics, 
benzodiazepines, statins, calcium channel blockers, protease inhibitors, oral 
contraceptives. Co-administration of potent liver enzyme inducers such as phenytoin 
and carbamazepine may increase metabolism of psoralen and result in a reduced 
response to PUVA. The risk of potential drug interactions further underscore the 
importance of MPD testing to ensure patient safety and also an adequate amount of 
psoralen in the skin at the correct time to allow the wanted phototoxic responses. 
 
f. Hepatotoxicity 
There are case reports of hepatitis following 5-MOP178,179 and 8-MOP.180-183 Importantly, 
two of the four cases arose in patients who had methotrexate-induced liver damage, and 
the remaining cases resolved once the drug was stopped. In one study of 162 patients 
receiving PUVA, only three patients had transient elevations of transaminases which all 
reverted to normal after treatment was stopped.184 The rarity of these cases, that have 
occurred with bath as well as oral PUVA, support the view that routine monitoring of liver 
function tests is not required. The mechanism is unclear and may be idiosyncratic.185 
 
g. Pain 
Severe skin pain with PUVA is uncommon and was seen in 4% (8/210) of patients 
treated with oral PUVA in one series.186 It is characterized by persistent severe prickling, 
burning or dysaesthesia which can last from minutes to hours and can persist for weeks 
or months. The risk of developing PUVA pain is unpredictable and does not appear to 
be related to the patient’s skin phototype, PUVA sensitivity or induction of PUVA 
phototoxicity. An underlying neurogenic mechanism appears most likely.187-189 
Treatment with analgesics, topical anaesthetics and topical or systemic steroids, usually 
has minimal effect. Capsaicin,190 gabapentin,191 phenytoin188 and low frequency 
electrotherapy192 can potentially be of benefit. Once PUVA pain has developed it is then 
a relative contraindication to further PUVA treatment as it is likely to recur.   
 
h. Miscellaneous 
Both allergic and photocontact allergic dermatitis to psoralens have been reported to 
affect 0.8% (3/371) of patients treated with topical PUVA.193 Type I anaphylaxis to both 
5-MOP194 and 8-MOP195 has also been observed in isolated cases and asthma may be 
aggravated.196-199 
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Hyperpigmentation is usually a result of repeated PUVA treatments but may also occur 
with the concurrent use of topical vitamin D analogues at treated lesional sites,200,201 and 
with concomitant treatment with isotretinoin.202  
 
Triggering of herpes simplex virus can occur with PUVA and use of high-factor 
sunscreen on the lips and prophylactic aciclovir for susceptible subjects is 
recommended. Eczema herpeticum has been reported in a patient with AD treated with 
PUVA.203 Folliculitis can occur and can be managed with applying emollients in a 
downward direction of the hair.   
 
Onycholysis following ingestion of phototoxic drugs is well documented. Onycholysis 
following ingestion of psoralens and natural sunlight has been observed and has also 
been reported following PUVA photochemotherapy.204 Other associated adverse events 
include lunular changes,205 subungual haemorrhage159 and nail pigmentation.159 
 
Clinically significant consistent changes in laboratory parameters are rarely observed.  
However, severe hyperlipidaemia following PUVA treatment for acute skin GVHD has 
been reported.206   
 
Other rare acute side effects of PUVA include bullous pemphigoid,207-209 lichen planus,210 
lichen planus pemphigoides,211 polymyositis,212  influenza-like symptoms,213  
lymphomatoid papulosis in a patient with mycosis fungoides214 and neurological 
disorders such as insomnia, nervousness, headache, migraine, dysomnia, depression 
and dizziness.215,216 The development of hypertrichosis, acne-like eruptions, milia and 
seborrhoeic-like facial dermatitis can also uncommonly occur and these changes are 
usually reversible on stopping treatment.159,217 An intertriginous, asymptomatic, self-
resolving, maculo-papular rash was reported in 8% of subjects undergoing 5-MOP 
PUVA and this resolved spontaneously despite continuation of PUVA.160 In one report 
three patients with mycosis fungoides developed new lesions at sites previously 
considered to be clear, early in the PUVA course. This might have been due to 
unmasking of sub-clinical lesions due to inflammation.218 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key points: 
 
Relatively common acute adverse effects of PUVA 
• Erythema 
• Pruritus 
• Nausea 
• Polymorphic light eruption 
 
Uncommon but important acute adverse effects of 
PUVA 
• PUVA pain 
• Idiosyncratic hepatitis 
• Psoralen allergy 
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10.2 Long term [Refer to online journal for full discussion]. 
 
10.2.1 PUVA induced skin cancer 
PUVA photochemotherapy is mutagenic,219-221 carcinogenic222,223 and immunosuppressive.224-
228 Skin cancer is a well-recognized side effect of PUVA and it is well established that the risk 
of squamous cell carcinoma (SCC) increases in a dose-dependent manner.229-234 Additional 
risk factors include exposure to co-carcinogenic therapeutic agents such as UVB therapy,235 
methotrexate,236,237 ciclosporin238 and X-ray radiation/arsenic.239-242 The human papilloma 
virus (HPV) has also been suggested as a co-carcinogen and has been detected in PUVA-
associated non-melanoma skin cancers (NMSCs), especially types associated with 
epidermodysplasia verruciformis, particularly types 5, 14 and 20.243-246 More recently, the USA 
16-centre, follow-up study has reported an increased incidence of melanoma in patients 
treated with PUVA,247,248 but it remains uncertain that this was a causative association and this 
association has not been reported by other groups.233,241,249,250 There is no evidence of either 
increased incidence of NMSC or melanoma in patients with psoriasis treated by topical 
PUVA.251,252 However, the number of patients with high PUVA exposure was low in these 
studies and many were treated with bath trimethylpsoralen PUVA. It seems likely that any 
differential risk of carcinogenicity relates more to differences in psoralens than different routes 
of administration, so it seems reasonable on the basis of current knowledge to believe that the 
risks per phototoxic exposure should be the same for oral 8-MOP PUVA as for bath 8-MOP 
PUVA.251 This is a reason why the (mainly historical) use of cumulative UVA dose with PUVA 
when considering action limits is less useful than considering number of treatments as 
cumulative UVA dose will always tend to be less with topical PUVA even when the number of 
phototoxic exposures is the same. 
 
a. PUVA and NMSC 
The two studies of most value in assessing NMSC risks in humans treated with PUVA 
were a North American study and a large Swedish study.231,232,249 The North American 
study involved use of maintenance PUVA, and only for one indication (that of psoriasis) in 
a fashion rarely used in Europe; the Swedish study used PUVA with a methodology close 
to that which is used in Europe and for a wide variety of indications. The North American 
study demonstrated that patients receiving more than 200 treatments have about 30 times 
the risk of developing a new NMSC per year than the general population.231 An almost 
identical risk was found in the highest risk group (men who had received 200 or more 
PUVA treatments) in the Swedish study.232 The relative risk amongst the highest-risk 
patients in the Swedish study of 30.7 meant 10 of 180 patients.232 A meta-analysis reported 
that the incidence of SCC among patients exposed to high-dose PUVA was 14-fold higher 
than among patients with low-dose exposure.253 The risk of skin cancer is persistent 
despite discontinuation of PUVA.254 Other risk factors for patients developing NMSC 
include being of lighter skin phototypes,255 having skin tumours prior to PUVA and age at 
starting PUVA,233 the presence of PUVA keratoses256 and lentigines.234,257   
 
PUVA-associated NMSCs show a reversal of the normal ratio of SCC to basal cell 
carcinoma (BCC) with a marked increase in SCC and these occur in relatively non-sun-
exposed sites.237 Genital SCC in males treated with PUVA has been reported to be 
substantially increased (95.7 times that of the general population),258,259 however, a lower 
incidence was reported in the Swedish study.232 A retrospective study from France of a 
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cancer registry over 20 years identified only one case of genital SCC in someone with a 
history of intensive PUVA, out of 48 cases of genital SCC. In addition, there were no 
reported cases of genital SCC from 5,400 patients who had received PUVA, despite lack 
of genital protection during PUVA exposures.260 Despite reports that SCC occurring in 
patients receiving PUVA are usually well differentiated and non-aggressive,231,233,242,255 
these tumours can rarely metastasize.237  
 
Lim et al. found high levels of UVB exposure (at least 300 treatments) to be associated 
with a modest but significant increase in SCC (x1.37) and BCC (x1.45) in the USA PUVA 
cohort.235 High level of exposure to methotrexate (total of 4 or more years of use) has also 
been found to be a significant independent risk factor in the latter cohort, with a relative 
risk of 2.1 for high versus low, or no exposure.237 Previously, a synergistic carcinogenic 
potential between methotrexate and PUVA had been suggested.236 Data also from the 
USA cohort showed that the risk of SCC in ciclosporin users was about three times higher 
than in patients who never used ciclosporin.238 PUVA patients who have previously 
received arsenic or X-ray therapy have an increased incidence of skin cancer compared 
with those who have not had such therapy.239,241,242 
  
b. Melanoma 
Patients who receive high doses of PUVA often develop lentigines which can show 
cytologically atypical melanocytes.261 A five-fold increase in annual incidence of malignant 
melanoma in the 16-centre PUVA cohort study, using PUVA to treat psoriasis, was initially 
reported in 1997.247 Further follow-up showed a nine-fold increase.248 Melanoma 
developed after 15 years and was more common in patients of skin types I/II and who had 
received at least 250 exposures. There have been a number of case reports of melanoma 
occurring following PUVA,262-270 but an increased incidence of melanoma has not been 
observed in European follow-up studies.233,241,250,271 So, while there is no doubt that an 
association between PUVA and melanoma was detected in this one study it is uncertain 
that PUVA causes melanoma. The association could have been because PUVA, as used 
in that study, did cause melanoma but equally the association could have been because 
of confounding (psoriasis patients responsive to PUVA seeking sunlight exposure, for 
example) or have been due to ascertainment bias (melanomas, and many were early 
melanomas some of which might not have progressed, more likely to be diagnosed in a 
prospectively followed group than in the general population).272 When it was first reported, 
the potential risk of melanoma induced by PUVA raised questions as to whether PUVA 
should be contraindicated in those with a history of more than 200 PUVA treatments or 
those with a personal or family history of melanoma.271,273 
 
c. Non-cutaneous cancer risk 
As PUVA alters immune function, especially the lymphocyte, there has been continued 
concern for the potential development of cancer particularly lymphoma with long-term use 
of this therapy. This is particularly relevant in psoriasis patients as an association with 
internal cancer has been found in large cohort studies,274,275 which includes tumours of 
oral and pharynx, lung, liver, pancreas, liver, bladder and lymphoma.276-278 However, 
previous studies have not demonstrated a consistent increase in cancer risk in the CNS,279 
thyroid,279 respiratory, pancreas and kidney.232,249  
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Though there are several case reports of leukaemia developing during PUVA therapy.280-
283 Stern et al. reported no increase of lymphoma or leukaemia in his PUVA cohort in either 
1988 or 1997,231,247 however, more recent analysis has found the incidence of lymphoma 
to be increased in this group in those exposed to high levels of methotrexate (RR 4.39), 
i.e. 36 months of treatment or longer, but not in those exposed to low levels.284 A study 
from Finland showed a 2.2-fold increase in non-Hodgkin’s lymphoma in patients 
hospitalized for psoriasis.277  
 
d. Non-cancerous chronic cutaneous side effects of PUVA 
Keratoses: these are typically localized to non-sun-exposed skin and risk factors for their 
development include increased age, male sex and high cumulative UVA dose.256 They are 
reported to occur in 46% of patients receiving high-dose (more than 2000 J/cm2) PUVA 
and show cytological atypia.234 Disseminated superficial actinic porokeratosis has been 
reported in association with both oral and topical PUVA.285-288 
 
Lentigines: PUVA-induced lentigines are distinct irregular, stellate, darkly pigmented 
macular lesions and may show cytological atypia.257,261 Incidence varies from 10% to 
53%,257,289-292 occurring most frequently in those patients exposed to high doses of 
PUVA234,257,291 and those of skin type I/II.289  
 
Dyspigmentation: PUVA-induced mottling consists of hyper- and hypopigmentation 
associated with atrophy which is mainly localized to areas of overdose.159,293 
Hyperpigmentation has been reported at the lesional sites of patients where calcipotriol 
ointment has been applied during bath PUVA.201 Transient hyperpigmentation has also 
been reported around psoriatic plaques in patients treated with calcipotriol ointment and 
PUVA.200 Acquired dermal melanocytosis typically affecting the back of Japanese patients 
treated with PUVA has been reported.294,295 
 
Photoageing: PUVA can result in dose-related premature ageing of the skin manifesting 
as wrinkling, xerosis, loss of elasticity, freckling, telangiectasia, mottled pigmentation, 
yellowing of the skin and comedones. More marked changes are seen in those of skin type 
I/II. Both epidermal and dermal changes have been reported with chronic PUVA exposure, 
including skin atrophy,296 focal epidermal297 and elastosis.  
 
Cataracts: Free 8-MOP can be detected in human lenses for at least 12 hours after 8-
MOP dosing.298 Previous guidelines from the British Photodermatology Group  recommend 
that protective eyewear be worn for 12 to 24 hours following PUVA and for 24 hours in 
high-risk individuals, e.g. patients with atopic eczema, children or those with pre-existing 
cataracts.299 Previous clinical studies (involving patients advised on eye protection), 
including the 16-centre prospective cohort study of USA psoriasis patients,300-302 have not 
detected an association between the use of PUVA and cataract development. A follow-up 
study of 82 patients who declined to wear UVA blocking sunglasses after PUVA treatments 
over 2 to 4 years found no evidence of the development of cataracts.303 
 
 
 
 
 
Key points: 
PUVA is associated with: 
• a significant dose-dependent risk of squamous cell 
carcinoma.  
• PUVA keratoses, pigmentary changes, and photoageing 
 
PUVA has not been consistently shown to be associated with: 
• melanoma  
• internal malignancy 
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10.3 How do we identify those who are susceptible to PUVA side effects? 
Careful patient selection is essential to prevent side effects, particularly skin cancer (see box 
below). PUVA should be used with care (generally only if the alteratives are treatments 
carrying greater risks, such as systemic immunosuppressives) in children due to the risk of 
causing UV cutaneous damage at a young age.  
 
There is concern that PUVA therapy may lead to worsening of human immunodeficiency virus 
(HIV) status or may increase risk of skin cancer in people with HIV,304-306 particularly as SCC 
and melanoma have been reported to be more aggressive in HIV disease.307,308 The risk of 
Merkel cell carcinoma of the skin was increased in the USA PUVA cohort309 by 100 times, and 
is also increased in HIV patients.310 However, studies to date of PUVA use in HIV-infected 
patients have not demonstrated a deterioration in HIV status or immune function,311-313 and it 
has been suggested that in fact, PUVA might be preferable to UVB therapy in those patients 
infected with HIV.314 
 
Patients who are at risk of ocular toxicity are those with pre-existing cataracts, patients who 
have AD or who are aphakic.  
 
 
RISK FACTORS ASSOCIATED WITH PUVA-INDUCED SKIN CANCER 
 
History 
 
• Sun-reactive skin phototype I/II 
• Previous history of skin cancer 
• Personal/family history of skin cancer or dysplastic naevus syndrome 
• Previous exposure to ionizing radiation, arsenic, excessive sunbed 
exposure 
• History of xeroderma pigmentosum or other genetic disorders associated 
with skin cancer 
• Patients on immunosuppressive drug therapy 
• HIV disease 
 
Examination 
 
• Multiple freckles/moles 
• Dysplastic naevi/solar keratoses/SCC in situ (Bowen’s disease) 
• Solar elastosis 
• Skin cancer 
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10.4 How can side effects be prevented in patients receiving PUVA therapy? 
Important measures to reduce skin cancer risk include the shielding of high-risk areas on the 
genitalia and face, education of patients regarding sun protective measures with sunscreen 
use and protective clothing, and monitoring for pre-malignant or malignant skin lesions. 
Patients who have received more than 150 to 200 PUVA treatments should be offered an 
annual skin examination to ensure no pre-malignant or malignant skin lesions have 
developed,159,299 and as a component to education of patients and their primary care doctors 
that they might be at increased risk of skin cancer as a result of medical treatment. Patients 
should be advised to wear protective UVA blocking glasses from the time they ingest psoralen 
until 12 hours following PUVA therapy and 24 hours for high-risk individuals, e.g. patients with 
atopic eczema, children or those with pre-existing cataracts.  Sunglasses or opaque UV 
protective glasses should be used315,316 and these can be tested for suitability.315,317 
Uncoloured glasses are, if there are any uncertainties about their ability to stop UVA 
transmission, more suitable than tinted glasses as the latter result in dilation of the pupil 
potentially allowing more UVA to reach the lens.318 Protective eyewear should be of sufficient 
size to reduce peripheral UV exposure and additional side protection is recommended. Most 
contact lenses have little or no UVA protection and are not recommended.319 
 
UVA-blocking goggles should be worn during PUVA therapy. As studies have not shown an 
increased incidence of cataracts, it has been suggested that an examination by an 
ophthalmologist should usually be considered only if the patient is at increased risk of 
cataracts,299 i.e. patients with pre-existing cataracts, who have AD or who are aphakic. 
 
As the risk of PUVA-induced skin cancer is related to the cumulative exposure, attempts 
should be made to reduce this exposure. This can be done in a number of ways including 
more efficient dosimetry using less intense PUVA treatment regimens,320,321 the avoidance of 
maintenance treatment,  following guidelines on action limit numbers of treatment exposures 
(e.g. 150 to 200 treatments),299 consideration of periods of breaks from PUVA with rotational 
therapy322 and the use of combination therapy with retinoids323 or topical vitamin D analogues. 
Retinoids not only increase the efficacy of PUVA but have a skin cancer prophylactic 
action.324,325 Concurrent use of PUVA with ciclosporin should be avoided as it can significantly 
accelerate skin cancer development in patients receiving such treatment.238 Topical vitamin D 
analogues and tazarotene have also been used as dose-sparing agents combined with 
PUVA.326,327 There may also be a role of potentially safer photosensitisers such as 
trimethylangelicin.328 Photochemotherapy using potentially safer wavelengths of radiation, e.g. 
NB-UVB requires further research.329,330 Agents which may protect against PUVA-induced 
photochemical damage, e.g. green tea or Polypodium leucotomos extract may decrease long-
term carcinogenesis.331,332 
 
Recommendation: (Strength of recommendation D; level of evidence 2+) 
 
• Concurrent use of PUVA with ciclosporin should be avoided. Post-PUVA ciclosporin is 
associated with increased risks of NMSCs and should be avoided when possible. 
However, previous use of ciclosporin should not preclude consideration for PUVA.  
 
10.5 How are the side effects managed in patients receiving PUVA therapy? 
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Pre-malignant and malignant skin lesions are treated in the same way as patients not receiving 
PUVA. PUVA requires to be discontinued if neoplastic lesions develop and alternative therapy 
should be considered but ciclosporin should be avoided.238 Introduction of acitretin can be 
helpful in management of patients with multiple keratoses and skin cancer following 
PUVA.324,325,333 These individuals will require careful follow-up as they are at increased risk of 
further skin cancers developing with time. 
 
10.6 PUVA and pregnancy 
As PUVA therapy is mutagenic there is concern regarding potential teratogenicity of this 
treatment. Oral psoralen is associated with reduced birth rate and teratogenicity in animal 
studies,334-336 but this is not found in humans.337-339 One study observed a marked increase in 
infants with low birth weights when pregnancy occurred after treatment.338 It was thought this 
may be an effect of the underlying disease rather than the treatment itself. Recently, it has 
been reported that pregnant women with severe psoriasis have a 1.4-fold increased risk of 
giving birth to infants with low birth weights.340 It has been suggested that local topical PUVA 
may be relatively safe in pregnancy as it does not give rise to detectable levels of psoralen.341 
It was recommended that PUVA therapy should be avoided during pregnancy whenever 
possible as it is mutagenic.337,342  
 
There is no evidence that PUVA is a significant teratogen. (Level of evidence 2++) 
 
Recommendation: (Strength of recommendation D; Level of evidence 4) 
 
• It is recommended that female patients should avoid conception during PUVA therapy  
and that, if despite this advice pregnancy does occur, PUVA should then be 
discontinued. 
 
 
11.0 PROTOCOLS AND PRACTICAL CONSIDERATIONS  
 
11.1 What is the optimum protocol for the delivery of PUVA therapy to optimize outcome 
in patients with psoriasis, eczema and PLE? 
 
Examples of treatment schedules commonly used in the UK can be accessed at:  
http://www.bad.org.uk/healthcare-professionals/clinical-services/service-
standards/phototherapy   
http://www.photonet.scot.nhs.uk [the Scottish national managed clinical network for 
phototherapyphotonet website] 
http://www.phototherapysupport.net [the south-east of England phototherapy network 
website] 
 
These may be used as guidance to the phototherapist in determining the optimum protocol.  
 
11.2 How should a PUVA therapy clinic be set up, taking account of:  
 
• equipment 
• staffing/training 
• support (e.g. medical physics, servicing) 
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• dosimetry/QA 
• records/database 
 
A Phototherapy Working Party Report has been produced by the BAD on the minimum 
standards for phototherapy services, and includes a phototherapy service review toolkit. 
http://www.bad.org.uk/healthcare-professionals/clinical-services/service-
standards/phototherapy  
 
In addition, the BPG has also published guidelines for dosimetry and calibration in ultraviolet 
radiation therapy.343 A joint BAD and BPG update of these guidelines is currently in press with 
the BJD.344 
http://www.bpg.org.uk/index.asp?SID=7&PID=13 
http://www.bad.org.uk/healthcare-professionals/clinical-standards/clinical-guidelines 
 
 
12.0 PRE-TREATMENT ASSESSMENT  
 
12.1 Risk assessment and patient counselling 
 
Prior to phototherapy, a formal risk assessment, which can be made by a nurse or a doctor, 
should include assessment of skin cancer risk, use of concomitant topical and systemic drugs, 
drug allergies, photosensitivity, liver or kidney disease and history of cataracts. 
• All patients who have had more than 150 to 200 exposures of PUVA should be offered 
annual assessment for any pre-malignant or malignant skin lesions. 
• Advice should be given on eye protection for 12 to 24 hours following oral PUVA, and 
considered for bath PUVA for widespread dermatoses, and for 24 hours in high-risk 
individuals, e.g. patients with atopic eczema, children or those with pre-existing 
cataracts or are aphakic. Eye protection should be worn when outdoors, when exposed 
to sunlight transmitting through window glass, and if exposed to indoor lighting capable 
of emitting ultraviolet A (including ‘energy saving’ compact fluorescent lamps) . 
• Advice should be given on photoprotection following each PUVA session, especially 
over the 12 hours after each treatment. 
• Informed consent should be taken and appropriate patient information leaflet provided. 
• Some examples of patient information leaflets can be viewed on: 
http://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=1644 
[page 35-38] 
http://www.phototherapysupport.net/view-document.asp?FileID=40 [appendix 
2, page 44-49] 
http://www.photonet.scot.nhs.uk/professionals-area/patient-information-
sheets/ 
  
12.2 Baseline investigations 
 
• In view of the minimal risk of hepatotoxicity, routine liver function tests are 
unnecessary, but should be performed to establish baseline levels in cases where 
there is known or suspected pre-existing liver dysfunction. 
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• There is no definite evidence that lupus can be induced or exacerbated by PUVA. The 
routine checking of antinuclear antibodies (ANA) is unnecessary, unless there is 
history of photosensitivity. 
• If the patient is at an increased risk of cataracts (e.g. children with atopic eczema), a 
baseline assessment by an ophthalmologist should be considered. 
• The MPD should be established to avoid phototoxicity and also, importantly, to ensure 
sufficient psoralen in the skin at the correct time.345 
 
 
13.0 FUTURE DIRECTIONS 
 
We have presented updated evidence to assist in the safe and effective use of PUVA therapy, 
although gaps still remain in direct evidence of comparison. Suggested areas for future 
research include: 
 
• A randomised comparative study, comparing PUVA with biological therapy for chronic 
plaque psoriasis; this would help guidance on whether to prescribe PUVA before 
biological therapies, taking into consideration the relative risks and efficacy.  
 
• A study to investigate whether or not there is an effect of MPD measurement at 72 and 
96 hours on erythemal episodes during PUVA and efficacy outcome measures.  
 
 
14.0 RECOMMENDED AUDIT POINTS 
 
(A) Is there a system in place to record and recall episodes of ‘burning’ which clearly: 
a. grades each episode 
b. reviews all episodes at 6-monthly intervals 
c. interprets the result in the context of the total number of treatments and total 
number of patients treated? 
 
(B) Over the past 12 months:  
1. Was there clear documentation of instances of painful erythema? 
2. Was there clear documentation of staff training records for topical and/or oral 
PUVA therapy? 
3. Was a patient information leaflet provided to: 
a. the last 20 consecutive patients receiving topical PUVA therapy? 
b. the last 50 consecutive patients receiving oral PUVA therapy? 
4. Was there clear documentation on advising patients on the risk of skin 
carcinogenicity on sun-exposed skin for: 
a. the last 20 consecutive patients receiving topical PUVA therapy?  
b. the last 50 consecutive patients receiving oral PUVA therapy?  
5. Was there clear documentation on advising patients on eye protection and UV 
protection following each oral PUVA treatment for the last 50 consecutive 
patients?  
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The audit recommendation of 20 or 50 cases per department is to reduce variation in the 
results due to a single patient, and allow benchmarking between different units. However, 
departments unable to achieve this recommendation may choose to audit all cases seen in 
the preceding 12 months. 
 
15.0 SUMMARY 
(See full manuscript for details of evidence) 
 
 Please see summary of recommendations for the safe and effective use of PUVA therapy in 
particular clinical situations (Table 4). 
 
Psoriasis All dermatology phototherapy units should offer bath PUVA as well as 
oral PUVA to treat psoriasis. (Strength of recommendation B) 
PUVA should usually be offered before oral systemic therapy for 
patients with chronic plaque psoriasis that has not responded 
adequately to other therapies including narrowband UVB. (Strength of 
recommendation B) 
PUVA should always be considered before biological therapy to treat 
chronic plaque psoriasis. (Strength of recommendation C) 
Although PUVA may occasionally be appropriate as a first-line 
phototherapy treatment for especially thick and/or extensive plaque 
psoriasis it should usually only be considered in patients with chronic 
plaque psoriasis, if NB-UVB has not been adequately effective.  
(Strength of recommendation B) 
Atopic eczema PUVA should be considered in patients with atopic eczema only if NB-
UVB has not been adequately effective. (Strength of recommendation 
D) 
Cutaneous T 
cell lymphoma 
of the mycosis 
fungoides (MF) 
type 
PUVA is the first line treatment for plaque-stage CTCL. (Strength of 
recommendation B) 
Maintenance therapy may be considered to prevent relapse in quickly 
recurrent plaque-stage CTCL. (Strength of recommendation D) 
NB-UVB is as effective as PUVA and is the treatment of choice for 
patch-stage CTCL. (Strength of recommendation D) 
Combination therapy with PUVA and interferon or retinoids/rexinoids 
should be considered in the treatment of early stage MF, if the response 
to monotherapy is slow. (Strength of recommendation B) 
Vitiligo PUVA should only be considered for widespread vitiligo if NB-UVB has 
been not shown to be adequately effective.  
(Strength of recommendation A) 
Polymorphic 
light eruption 
PUVA should be considered if UVB has failed, or has previously 
triggered the eruption sufficiently to compromise a course of therapy, or 
if there are other practical issues. PUVA should be considered before 
other systemic treatments. (Strength of recommendation D) 
Chronic actinic 
dermatitis 
(CAD) 
In the treatment of CAD, PUVA therapy should be considered in a 
specialist unit experienced with managing this disease, with full 
knowledge of the individual patient’s action spectrum. Special 
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precautions including inpatient supervision, topical/oral corticosteroid 
cover may be required. (Strength of recommendation D) 
Idiopathic solar 
urticaria (SU) 
In the management of SU (after full assessment including definition of the 
action spectrum), PUVA can be considered. The treatment should be 
carried out with full knowledge of the patient’s action spectrum, in a 
specialist unit experienced with managing this disease. (Strength of 
recommendation D) 
Erythropoietic 
protoporphyria 
(EPP) 
PUVA is rarely appropriate in EPP, NB-UVB is the phototherapy of first 
choice.  
(Strength of recommendation D) 
Actinic prurigo 
(AP) 
NB-UVB may be a safer therapeutic option in terms of phototherapy-
associated carcinogenic risk in patients with AP, particularly in children, 
and should be considered before PUVA.  
(Strength of recommendation D) 
Hyperkeratotic 
palmoplantar 
eczema 
Oral PUVA should usually be considered as the first-line PUVA 
treatment for patients with palmoplantar dermatoses.  
(Strength of recommendation D(GPP)) 
Palmoplantar 
psoriasis 
PUVA using topical or oral psoralen should be considered as a 
treatment for palmoplantar psoriasis. (Strength of recommendation C) 
Palmoplantar 
pustulosis 
 
PUVA using oral psoralen should be considered as a treatment for 
palmoplantar pustulosis. (Strength of recommendation C) 
Unless there are contraindications, the combination of oral PUVA with 
oral retinoids should be considered as a treatment for palmoplantar 
pustulosis. (Strength of recommendation A) 
Pregnancy It is recommended that female patients should avoid conception during 
PUVA therapy and that if despite this advice pregnancy does occur, 
PUVA should be discontinued. (Strength of recommendation D) 
 
Table 4. Recommendations in particular clinical situations 
 
SUPPORTING INFORMATION 
Additional supporting information including the search strategy may be found in the online 
version of this article. 
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APPENDIX 1 
 
Levels of evidence 
Level of evidence Type of evidence 
1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a 
very low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs 
with a low risk of bias 
1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of 
bias* 
2++ High-quality systematic reviews of case-control or cohort studies 
High-quality case-control or cohort studies with a very low risk of 
confounding, bias or chance and a high probability that the relationship is 
causal 
2+ Well-conducted case-control or cohort studies with a low risk of 
confounding, bias or chance and a moderate probability that the 
relationship is causal 
2- Case-control or cohort studies with a high risk of confounding, bias or 
chance and a significant risk that the relationship is not causal* 
3 Non-analytical studies (for example, case reports, case series) 
4 Expert opinion, formal consensus 
*Studies with a level of evidence ‘-’ should not be used as a basis for making a 
recommendation. 
 
Strength of recommendation 
Class Evidence 
A • At least one meta-analysis, systematic review, or RCT rated as 1++, and 
directly applicable to the target population, or 
• A systematic review of RCTs or a body of evidence consisting principally 
of studies rated as 1+, directly applicable to the target population and 
demonstrating overall consistency of results 
• Evidence drawn from a NICE technology appraisal 
B • A body of evidence including studies rated as 2++, directly applicable to 
the target population and demonstrating overall consistency of results, or 
• Extrapolated evidence from studies rated as 1++ or 1+ 
C • A body of evidence including studies rated as 2+, directly applicable to 
the target population and demonstrating overall consistency of results, or 
• Extrapolated evidence from studies rated as 2++  
D • Evidence level 3 or 4, or 
• Extrapolated evidence from studies rated as 2+, or 
• Formal consensus 
D (GPP) • A good practice point (GPP) is a recommendation for best practice based 
on the experience of the guideline development group 
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RCT: randomised controlled trial; NICE: National Institute for Health and Clinical Excellence. 
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Advantages of oral PUVA Advantages of topical PUVA 
Shorter overall outpatient attendance times No risk of gastrointestinal adverse effects 
Less staff involvement Drug interactions unlikely 
Less risk of phototoxic reactions from natural 
UV exposure (lower concentration of 
psoralen in the skin after treatment) 
Eye protection not always required 
Only practical option for whole-body 
treatment for units with inadequate bath 
facilities 
Shorter periods in treatment cubicle due to 
smaller dose of UVA 
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1st author Publication 
year 
Bath 
psoralen 
Oral 
psoralen 
UVA regimen Randomised
? 
Blinded? Proportion 
(percentage) 
cleared with 
oral PUVA 
Proportion 
(percentage) 
cleared with 
bath PUVA 
Difference (% more clearing 
with oral PUVA); 95% CI for 
difference 
Turjanmaa12 1985 TMP 3 
mg/l  
8-MOP 0.6 
mg/Kg 
arbitrary starting 
doses; 3 times a 
week; 
incremental 
regimen not 
reported 
No No 37/43 (86%) 42/50 (84%) 2%; -12% to 17% 
Lowe13 1986 3.75 mg/l 8-MOP 0.6 
mg/Kg 
Skin phototype 
based starting 
dose and 
incremental 
regimen 
No No 8/20 (40%) 8/20 (40%)  0%; -30% to 30% 
Collins10 1992 8-MOP 
3.78 mg/l 
8-MOP 0.6 
mg/Kg 
skin phototype 
based starting 
doses; 3 times a 
week; no > 20 
treatments 
Yes (but 
allocation 
not 
concealed) 
No 14/22 (64%) 
 
14/22 (64%) 0%; -28% to 28% 
Cooper11 2000 8-MOP 
2.6 mg/l 
8-MOP 0.6 
mg/Kg 
70% MPD starting 
dose; 2 times a 
week; percentage 
based 
incremental 
regimen 
Yes (but 
allocation 
not 
concealed) 
No 14/17 (82%) 17/17 
(100%) 
-18%; -36% to 0.5% 
Table 2. Controlled studies comparing whole-body topical PUVA (‘bath PUVA’) with oral PUVA 
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Phototherapy 
type 
Rash 
provocation 
Erythema Pruritus 
Herpes 
simplex 
PUVA 12-50% 8-67% 18-33% -- 
NB-UVB 62% 54% 15% -- 
BB-UVB  53% 27% 40% 20% 
 
Table 3. Incidence of side effects with different phototherapy 
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1st Author Year n= % more cleared 
with oral PUVA 
(95% CI) 
 
 
Turjanmaa12 
 
1985 
 
93 
 
2% (-12% to 17%) 
 
 
Lowe13 
 
1986 
 
40 
 
0% (-30% to 30%) 
Collins10 1992 44 0% (-28% to 28%) 
Cooper11 2000 34 -18% (-36% to 
0.5%) 
 
 
Figure 1. Controlled study (including RCTs by Collins et al. and Cooper et al.) comparisons 
of oral PUVA with bath PUVA for psoriasis 
 
 
 
1st Author Year n= % more cleared with 
oral PUVA (95% CI) 
 
 
 
Sivanesan16 
 
 
2009 
 
 
40 
 
 
2% (-12% to 17%) 
 
 
 
 
 
 
Figure 2. RCT comparing PUVA with placebo for psoriasis 
  
oral PUVA better bath PUVA better 
PUVA better placebo 
better 
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1st 
Author 
Year Systemic Outcome n= % more 
cleared with 
systemic 
(95% CI) 
 
 
Nugteren
-Huying17 
 
1990 
 
Fumaric acid 
esters 
 
‘clear’ at 
16 weeks 
 
24 
 
42% (9% to 74%) 
 
 
Ellis18 
 
1991 
Ciclosporin 
7.5 
mg/Kg/day 
‘clear or 
almost 
clear’ by 8 
weeks 
 
40 
 
80% (60% to 
100%) 
Ellis18 1991 
Ciclosporin 5 
mg/Kg/day 
‘clear or 
almost 
clear’ by 8 
weeks 
45 65% (44% to 
86%) 
Ellis18 1991 
Ciclosporin 3 
mg/Kg/day 
‘clear or 
almost 
clear’ by 8 
weeks 
50 36% (17% to 
55%) 
Saurat19 2008 
 
Methotrexate 
PASI 75% 
reduction 163 17% (3% to 30% 
 
 
Figure 3. RCTs comparing conventional systemic therapies with placebo for psoriasis 
 
  
systemic better placebo 
better 
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Biological 
drug 
n=  
(number treated 
with biological) 
% more reaching PASI 75 
with PUVA than with 
biological (95% CI) 
 
 
Adalimumab 
 
18 
 
30% (6% to 54%) 
 
 
Alefacept 
 
32 
 
60% (44% to 77%) 
Efalizumab 17 27% (2.5% to 51%) 
Etanercept 38 46% (29% to 63%) 
Infliximab 7 -14% (-21% to -8% 
Ustekinumab 18 19 (-4% to 42%) 
 
 
Figure 4. Retrospective comparison of PUVA (n = 118 patients) with biologicals, Inzinger et 
al.7 Baseline mean PASI for PUVA was 15 and for biologicals was 16.9. Outcome of PASI 
75% reduction. 
 
  
PUVA better biological 
better 
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Biological 
drug 
n=  
(number treated 
with biological) 
% more reaching PASI 90 
with PUVA than with 
biological (95% CI) 
 
 
Adalimumab 
 
18 
 
47% (26% to 68%) 
 
 
Alefacept 
 
32 
 
66% (54% to 77%) 
Efalizumab 17 64% (50% to 78%) 
Etanercept 38 57% (41% to 72%) 
Infliximab 7 -2% (-36% to 33%) 
Ustekinumab 18 31 (7% to 55%) 
 
 
Figure 5. Retrospective comparison of PUVA (n = 118 patients) with biologicals, Inzinger et 
al.7 Baseline mean PASI for PUVA was 15 and for biologicals was 16.9. Outcome of PASI 90% 
reduction (similar outcome measure to ‘clearance’ or ‘minimal residual activity’). 
PUVA better biological 
better 
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1st Author Year Design NB-UVB PUVA Outcome Total n= % more cleared 
with PUVA (95% CI) 
 
van 
Weelden24 
 
1990 
controlled, paired, 
inpatients 
2 times a 
week 
2 times a week, oral 8-
MOP 
better treatment by 4 weeks  
10 
 
10% (-43% to 63%) 
 
 
Tanew25 
 
1999 
controlled, paired 3 times a 
week 
3 times a week, oral 
liquid formulation 
(rapidly absorbed) 
better response 
 
25 
 
28% (-4% to 60%) 
Gordon26 1999 
randomised, 
parallel group 
2 times a 
week 
2 times a week, oral 8-
MOP clearance by end course 100 21% (4% to 38%) 
Gordon26 1999 
randomised, 
parallel group 
2 times a 
week 
2 times a week oral 8-
MOP still clear at 6 months 100 21% (5% to 37%) 
Dawe27 2003 
randomised, paired 3 times a 
week 
2 times a week, TMP 
bath PUVA clearance/MRA by end course 28 -21% (-6% to-37%) 
Markham28 2003 
randomised, 
parallel group 
3 times a 
week 
2 times a week, oral 8-
MOP clearance by end course 54 1% (-19% to 21%)) 
Markham28 2003 
randomised, 
parallel group 
3 times a 
week 
2 times a week, oral 8- 
MOP still clear at 6 months 54 -3% (-30% to 23%) 
Snellman29 2004 
randomised, paired 3 times a 
week 
3 times a week 
excellent clinical response 18 -33% (-6% to -61%) 
Yones30 2006 
randomised, 
parallel group 
2 times a  
week 
2 times a week, oral 8-
MOP clearance at end course 71 (excluded 
SPT V & VI) 
19% (-1% to 39%) 
Salem31 2010 
controlled, parallel 
group 
3 times a 
week 
3 times a week, bath 
8-MOP clearance at end course 34 49% (21% to 76%) 
Chauhan33 2011 
randomised, 
parallel group 
3 times a 
week 
3 times a week, oral 8-
MOP marked improvement 51 1% (-22% to 24%) 
 
Figure 6. Controlled studies comparing PUVA with narrowband UVB for psoriasis 
NB-UVB 
better 
PUVA 
better 
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1st Author Year Design NB-UVB PUVA Outcome Total n= % more cleared 
with PUVA (95% 
CI) 
 
 
Westerhof57 1997 
controlled (alternate 
allocation), parallel 
group 
2 times a 
week 
0.005% psoralen gel, 
2 times a week 
 
any repigmentation by  4 
months 
106 -27% (-48% to -6%) 
 
 
Bhatnagar58 
 
2007 
Controlled 
(“randomly 
allocated”), parallel 
group 
3 times a 
week, 
reducing to 2 
times a week 
 
oral TMP 0.6mg/Kg 
repigmentation of >50% at 
end of treatment (up to 1 
year therapy) 
 
50 
 
-20% (-47% to 7%) 
Yones6 2007 
 
randomised, 
parallel group 
 
2 times a 
week 
oral 8-MOP (or 5-
MOP if intolerant of 
8-MOP because of 
nausea) 2 times a 
week 
repigmentation of >50% at 
end of treatment course 
50 -28% (-55% to -1%) 
Yones6 2007 
 
randomised, 
parallel group 
 
2 times a 
week 
oral 8-MOP (or 5-
MOP if intolerant of 
8-MOP because of 
nausea) 2 times a 
week 
repigmentation of >75% at 
end of treatment course 
50 -12% (-36% to 12%) 
Yones6 2007 
randomised, parallel 
group 
2 times a 
week 
oral 8-MOP (or 5-
MOP if intolerant of 
8-MOP because of 
nausea) 2 times a 
week 
repigmentation of still 
>75% compared to before 
course on follow-up  12 
months after end course  
50 -12% (-37% to 13%) 
 
 
Figure 7 Controlled studies comparing PUVA with narrowband UVB for vitiligo 
 
PUVA 
better 
NB-UVB 
better 
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